- Home
- NVVE vs DRMA Comparison
NVVE vs DRMA Comparison
Compare NVVE & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- DRMA
- Stock Information
- Founded
- NVVE 1996
- DRMA 2014
- Country
- NVVE United States
- DRMA United States
- Employees
- NVVE N/A
- DRMA N/A
- Industry
- NVVE Oil Refining/Marketing
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- NVVE Energy
- DRMA Health Care
- Exchange
- NVVE Nasdaq
- DRMA Nasdaq
- Market Cap
- NVVE 5.5M
- DRMA 4.5M
- IPO Year
- NVVE N/A
- DRMA 2021
- Fundamental
- Price
- NVVE $0.95
- DRMA $0.59
- Analyst Decision
- NVVE
- DRMA Strong Buy
- Analyst Count
- NVVE 0
- DRMA 1
- Target Price
- NVVE N/A
- DRMA $3.00
- AVG Volume (30 Days)
- NVVE 2.2M
- DRMA 94.2K
- Earning Date
- NVVE 08-12-2025
- DRMA 08-06-2025
- Dividend Yield
- NVVE N/A
- DRMA N/A
- EPS Growth
- NVVE N/A
- DRMA N/A
- EPS
- NVVE N/A
- DRMA N/A
- Revenue
- NVVE $5,440,777.00
- DRMA N/A
- Revenue This Year
- NVVE $892.33
- DRMA N/A
- Revenue Next Year
- NVVE N/A
- DRMA N/A
- P/E Ratio
- NVVE N/A
- DRMA N/A
- Revenue Growth
- NVVE N/A
- DRMA N/A
- 52 Week Low
- NVVE $0.82
- DRMA $0.57
- 52 Week High
- NVVE $8.80
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- NVVE 42.76
- DRMA 29.24
- Support Level
- NVVE $1.22
- DRMA $0.57
- Resistance Level
- NVVE $1.54
- DRMA $0.63
- Average True Range (ATR)
- NVVE 0.16
- DRMA 0.04
- MACD
- NVVE -0.04
- DRMA -0.01
- Stochastic Oscillator
- NVVE 9.73
- DRMA 11.55
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.